23 related articles for article (PubMed ID: 38672477)
1. PL-hMSC and CH-hMSC derived soluble factors inhibit proliferation but improve hGBM cell migration by activating TGF-β and inhibiting Wnt signaling.
Uthanaphun T; Manochantr S; Tantrawatpan C; Tantikanlayaporn D; Kheolamai P
Biosci Rep; 2024 May; 44(5):. PubMed ID: 38687607
[TBL] [Abstract][Full Text] [Related]
2. Significance of serglycin and its binding partners in autocrine promotion of metastasis in esophageal cancer.
Zhu Y; Lam AKY; Shum DKY; Cui D; Zhang J; Yan DD; Li B; Xu WW; Lee NPY; Chan KT; Law S; Tsao SW; Cheung ALM
Theranostics; 2021; 11(6):2722-2741. PubMed ID: 33456569
[No Abstract] [Full Text] [Related]
3. Cancer-associated fibroblasts secrete hypoxia-induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/β-catenin pathway.
Xie J; Qi X; Wang Y; Yin X; Xu W; Han S; Cai Y; Han W
Cell Oncol (Dordr); 2021 Jun; 44(3):661-671. PubMed ID: 33651283
[TBL] [Abstract][Full Text] [Related]
4. Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44.
Guo JY; Chiu CH; Wang MJ; Li FA; Chen JY
J Biomed Sci; 2020 Jan; 27(1):2. PubMed ID: 31898491
[TBL] [Abstract][Full Text] [Related]
5. Serglycin promotes breast cancer cell aggressiveness: Induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling.
Bouris P; Manou D; Sopaki-Valalaki A; Kolokotroni A; Moustakas A; Kapoor A; Iozzo RV; Karamanos NK; Theocharis AD
Matrix Biol; 2018 Dec; 74():35-51. PubMed ID: 29842969
[TBL] [Abstract][Full Text] [Related]
6. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.
Guo JY; Hsu HS; Tyan SW; Li FY; Shew JY; Lee WH; Chen JY
Oncogene; 2017 Apr; 36(17):2457-2471. PubMed ID: 27819672
[TBL] [Abstract][Full Text] [Related]
7. Tumorigenic functions of serglycin: Regulatory roles in epithelial to mesenchymal transition and oncogenic signaling.
Manou D; Karamanos NK; Theocharis AD
Semin Cancer Biol; 2020 May; 62():108-115. PubMed ID: 31279836
[TBL] [Abstract][Full Text] [Related]
8. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
Nana AW; Yang PM; Lin HY
Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
[TBL] [Abstract][Full Text] [Related]
9. Biologically Active TNIIIA2 Region in Tenascin-C Molecule: A Major Contributor to Elicit Aggressive Malignant Phenotypes From Tumors/Tumor Stroma.
Iyoda T; Fujita M; Fukai F
Front Immunol; 2020; 11():610096. PubMed ID: 33362799
[TBL] [Abstract][Full Text] [Related]
10. Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.
Shi Y; Kong Z; Liu P; Hou G; Wu J; Ma W; Cheng X; Wang Y
Cells; 2021 May; 10(5):. PubMed ID: 34068501
[TBL] [Abstract][Full Text] [Related]
11. The Expression of Serglycin Is Required for Active Transforming Growth Factor β Receptor I Tumorigenic Signaling in Glioblastoma Cells and Paracrine Activation of Stromal Fibroblasts via CXCR-2.
Manou D; Golfinopoulou MA; Alharbi SND; Alghamdi HA; Alzahrani FM; Theocharis AD
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672477
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
